Evidence map›Paper›PMID 37298228›Full record

ArticleInternational journal of molecular sciences2023

Effects of Phosphorylation on the Activity, Inhibition and Stability of Carbonic Anhydrases.

Xiaojing Huang, Daniel Winter, Dominic J Glover, Claudiu T Supuran, William A Donald

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Xiaojing HuangSchool of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia.
Daniel WinterSchool of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia.
Dominic J GloverSchool of Biotechnology & Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia.
Claudiu T SupuranNeurofarba Department, Sezione di Scienze Farmaceutiche, Universita degli Studi di Firenze, Via Ugo Schiff 6, Sesto Fiorentino, 50019 Florence, Italy.ORCID 0000-0003-4262-0323
William A DonaldSchool of Chemistry, University of New South Wales, Sydney, NSW 2052, Australia.ORCID 0000-0002-6622-8193
UNSW Sydney · AUUniversity of Florence · IT

Funding

Australian Research Council DP190103298Australian Research Council FT200100798
6 · The paper itself

Abstract

Carbonic anhydrases (CAs) are a metalloenzyme family that have important roles in cellular processes including pH homeostasis and have been implicated in multiple pathological conditions. Small molecule inhibitors have been developed to target carbonic anhydrases, but the effects of post-translational modifications (PTMs) on the activity and inhibition profiles of these enzymes remain unclear. Here, we investigate the effects of phosphorylation, the most prevalent carbonic anhydrase PTM, on the activities and drug-binding affinities of human CAI and CAII, two heavily modified active isozymes. Using serine to glutamic acid (S > E) mutations to mimic the effect of phosphorylation, we demonstrate that phosphomimics at a single site can significantly increase or decrease the catalytic efficiencies of CAs, depending on both the position of the modification and the CA isoform. We also show that the S > E mutation at Ser50 of hCAII decreases the binding affinities of hCAII with well-characterized sulphonamide inhibitors including by over 800-fold for acetazolamide. Our findings suggest that CA phosphorylation may serve as a regulatory mechanism for enzymatic activity, and affect the binding affinity and specificity of small, drug and drug-like molecules. This work should motivate future studies examining the PTM-modification forms of CAs and their distributions, which should provide insights into CA physiopathological functions and facilitate the development of 'modform-specific' carbonic anhydrase inhibitors.

Indexed as

Carbonic AnhydrasesCarbonic Anhydrase IICarbonic Anhydrase InhibitorsCarbonic Anhydrase IXCatalytic DomainHumansPhosphorylationCarbonic Anhydrase IICarbonic Anhydrase InhibitorsCarbonic Anhydrase IXCarbonic Anhydrasescarbonic anhydrase inhibitionesterase activityhuman carbonic anhydrase Ihuman carbonic anhydrase IIphosphorylationpost-translational modificationssulphonamides

Identifiers

PMID37298228
PMCPMC10253321
OpenAlexW4378472834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.